Monoclonal antibodies for Hodgkin disease
Antibodies are proteins made by the immune system to help fight infections. Man-made versions, called monoclonal antibodies, can be designed to attack a target, such as a substance on the surface of lymphocytes (the cells in which Hodgkin disease starts).
Some monoclonal antibodies are now being used to treat Hodgkin disease, including brentuximab vedotin (Adcetris®) and rituximab (Rituxan®). The drugs are given as an IV infusion, in the doctor’s office or clinic, usually once every few weeks.
Common side effects are usually mild but can include chills, fever, nausea, rashes, fatigue, and headaches. Rarely, more severe side effects occur.
Last Medical Review: 08/19/2014
Last Revised: 01/13/2015